(3-methoxy-1-methoxymethylpropyl)-[2-methyl-7-(2,4,6-trimethylphenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-b]pyridin-3-yl]-amine | 540780-71-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (3-methoxy-1-methoxymethylpropyl)-[2-methyl-7-(2,4,6-trimethylphenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-b]pyridin-3-yl]-amine
• 英文别名: N-(1,4-dimethoxybutan-2-yl)-2-methyl-7-(2,4,6-trimethylphenyl)-5,6-dihydro-4H-pyrazolo[3,4-b]pyridin-3-amine
• CAS: 540780-71-0
• 化学式: C₂₂H₃₄N₄O₂
• 分子量: 386.538
• InChiKey: JRFPKTOUTCWAJJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  51.6
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Heterocyclic GABAA subtype selective receptor modulators
  申请人：Loughhead Garrett David

  公开号：US20050197330A1

  公开（公告）日：2005-09-08

  This invention relates to a method for modulating α 2 subtype GABA A receptors with heterocyclic compounds of formula I, and salts, solvates and prodrugs thereof. The invention further relates to novel heteocyclic compounds and pharmaceutical compositions containing said compounds. In addition the invention relates to the treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder or pain

  这项发明涉及一种用式I的杂环化合物调节α2亚型GABAA受体的方法，以及其盐、溶剂合物和前药。该发明还涉及新型杂环化合物和含有该化合物的药物组合物。此外，该发明涉及治疗抑郁症、焦虑障碍、精神障碍、学习或认知障碍、睡眠障碍、癫痫或抽搐障碍或疼痛。
• Ring fused pyrazole derivatives as CRF antagonists
  申请人：Loughhead Garrett David

  公开号：US20060135555A1

  公开（公告）日：2006-06-22

  This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein Ar is optionally substituted aryl or heteroaryl, R 1 -R 4 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents.

  本发明涉及化合物，通常为CRF-1受体拮抗剂，其由公式I或公式II表示：其中Ar是可选的取代芳基或杂环芳基，R1-R4如规范所定义；或其单一异构体，外消旋或非外消旋异构体混合物，或其药学上可接受的盐。本发明还涉及制备这种化合物的方法，含有这种化合物的制药组合物，以及将其用作治疗剂的方法。
• RING FUSED PYRAZOLE DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1453832B1

  公开（公告）日：2006-08-09
• US6821984B2
  申请人：——

  公开号：US6821984B2

  公开（公告）日：2004-11-23
• US7053103B2
  申请人：——

  公开号：US7053103B2

  公开（公告）日：2006-05-30